Found: 36
Select item for more details and to access through your institution.
Driver mutation‐specific clinical and genomic correlates differ between primary and secondary myelofibrosis.
- Published in:
- American Journal of Hematology, 2019, v. 94, n. 12, p. E314, doi. 10.1002/ajh.25625
- By:
- Publication type:
- Article
Genetically inspired prognostic scoring system (GIPSS) outperforms dynamic international prognostic scoring system (DIPSS) in myelofibrosis patients.
- Published in:
- American Journal of Hematology, 2019, v. 94, n. 1, p. 87, doi. 10.1002/ajh.25335
- By:
- Publication type:
- Article
Acquisition of IDH2 mutations in relapsed/refractory AML is associated with worse patient outcomes.
- Published in:
- European Journal of Haematology, 2021, v. 107, n. 6, p. 609, doi. 10.1111/ejh.13698
- By:
- Publication type:
- Article
CPX-351 Yields Similar Response and Survival Outcome in Younger and Older Patients With Secondary Acute Myeloid Leukemia.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 10, p. 774, doi. 10.1016/j.clml.2022.06.001
- By:
- Publication type:
- Article
MPN-244: Comorbid Conditions Occur Frequently and Correlate with Early Disease Progression and Poor Outcomes in Young Patients with Myelofibrosis.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S358, doi. 10.1016/S2152-2650(21)01826-7
- By:
- Publication type:
- Article
MPN-236: Different Treatment Approaches to Blast-Phase Myeloproliferative Neoplasms.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S358, doi. 10.1016/S2152-2650(21)01825-5
- By:
- Publication type:
- Article
AML-407: Mutations Highly Specific for Secondary AML are Associated with Poor Outcomes Even in Patients with NPM1 Mutated ELN Favorable Risk AML.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S309, doi. 10.1016/S2152-2650(21)01733-X
- By:
- Publication type:
- Article
AML-170: High MYC Expression Predicts Poor Survival Outcomes in IDH1/2 Mutant AML Patients.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S286, doi. 10.1016/S2152-2650(21)01686-4
- By:
- Publication type:
- Article
Poster: MPN-244: Comorbid Conditions Occur Frequently and Correlate with Early Disease Progression and Poor Outcomes in Young Patients with Myelofibrosis.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S232, doi. 10.1016/S2152-2650(21)01460-9
- By:
- Publication type:
- Article
Poster: MPN-236: Different Treatment Approaches to Blast-Phase Myeloproliferative Neoplasms.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S232, doi. 10.1016/S2152-2650(21)01459-2
- By:
- Publication type:
- Article
Poster: AML-407: Mutations Highly Specific for Secondary AML are Associated with Poor Outcomes Even in Patients with NPM1 Mutated ELN Favorable Risk AML.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S214, doi. 10.1016/S2152-2650(21)01345-8
- By:
- Publication type:
- Article
Poster: AML-170: High MYC Expression Predicts Poor Survival Outcomes in IDH1/2 Mutant AML Patients.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S212, doi. 10.1016/S2152-2650(21)01331-8
- By:
- Publication type:
- Article
Evaluating Predictors of Immune-Related Adverse Events and Response to Checkpoint Inhibitors in Myeloid Malignancies.
- Published in:
- 2021
- By:
- Publication type:
- letter
Fluorescence in Situ Hybridization (FISH) Utility for Risk Score Assessment in Patients With MDS With Normal Metaphase Karyotype.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Retrospective Analysis of the Clinical Use and Benefit of Lenalidomide and Thalidomide in Myelofibrosis.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Defining Acute Myeloid Leukemia Ontogeny in Older Patients.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Lenalidomide and Thalidomide are Active in MF-Related Anemia, but Differ in Duration of Response and Association of Benefit with Outcome.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. S350, doi. 10.1016/j.clml.2019.07.363
- By:
- Publication type:
- Article
Hypoplastic MDS in the Elderly: A Single Institutional Experience.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. S341, doi. 10.1016/j.clml.2019.07.344
- By:
- Publication type:
- Article
Venetoclax Combination with Hypomethylating Agents for Treatment of Myelodysplastic Syndromes.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. S339, doi. 10.1016/j.clml.2019.07.340
- By:
- Publication type:
- Article
RUNX1 Mutation is Associated with Poor Outcome in Patients with Acute Myeloid Leukemia (AML) who Received Allogeneic Stem Cell Transplantation (allo-SCT).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. S233, doi. 10.1016/j.clml.2019.07.119
- By:
- Publication type:
- Article
Impact of the Number of Consolidation Chemotherapy Cycles Prior to Allogeneic Stem Cell Transplant for Adults with Acute Myeloid Leukemia in First Remission.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. S222, doi. 10.1016/j.clml.2019.07.098
- By:
- Publication type:
- Article
SOHO State of the Art and Next Questions: Management of Myelodysplastic Syndromes With Deletion 5q.
- Published in:
- 2018
- By:
- Publication type:
- journal article
When Two Roads Diverge: Genetically Inspired Prognostic Scoring System (GIPSS) Outperforms DIPSS in Myelofibrosis Patients where the Two Risk Models Widely Differ.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2018, v. 18, p. S266, doi. 10.1016/j.clml.2018.07.183
- By:
- Publication type:
- Article
Hypomethylating Agents Versus Intensive Chemotherapy in Older Patients (Age ≥ 70) with Acute Myeloid Leukemia with High White Blood Cell Count.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2018, v. 18, p. S201, doi. 10.1016/j.clml.2018.07.051
- By:
- Publication type:
- Article
The Treatment Landscape of Myelofibrosis Before and After Ruxolitinib Approval.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Improved Responses with Azacitidine Compared to Decitabine in Patients with Acute Myeloid Leukemia in Patients ≥70 with Poor-Risk Cytogenetics.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. S295, doi. 10.1016/j.clml.2017.07.085
- By:
- Publication type:
- Article
Monocytosis in myelofibrosis is associated with clinical outcome, hematologic abnormalities and somatic mutations.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. S357, doi. 10.1016/j.clml.2017.07.188
- By:
- Publication type:
- Article
Serum Albumin as Prognostic Factor for Overall Survival in Rearranged MYC and BCL2/BCL6 Positive Double Hit Diffuse Large B Cell Lymphomas.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2016, v. 16, p. S99, doi. 10.1016/j.clml.2016.07.142
- By:
- Publication type:
- Article
Comparing Eras in Myelofibrosis: Changing Patterns of Treatment Before and After FDA-Approval of Ruxolitinib.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2016, v. 16, p. S91, doi. 10.1016/j.clml.2016.07.128
- By:
- Publication type:
- Article
Myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T): Mayo-Moffitt collaborative study of 158 patients.
- Published in:
- Blood Cancer Journal, 2022, v. 12, n. 2, p. 1, doi. 10.1038/s41408-022-00622-8
- By:
- Publication type:
- Article
Molecular characteristics and outcomes in Hispanic and non‐Hispanic patients with acute myeloid leukemia.
- Published in:
- EJHaem, 2022, v. 3, n. 4, p. 1231, doi. 10.1002/jha2.589
- By:
- Publication type:
- Article
An Exercise in Extrapolation: Clinical Management of Atypical CML, MDS/MPN-Unclassifiable, and MDS/MPN-RS-T.
- Published in:
- Current Hematologic Malignancy Reports, 2016, v. 11, n. 6, p. 425, doi. 10.1007/s11899-016-0350-1
- By:
- Publication type:
- Article
Molecular annotation of extramedullary acute myeloid leukemia identifies high prevalence of targetable mutations.
- Published in:
- Cancer (0008543X), 2022, v. 128, n. 21, p. 3880, doi. 10.1002/cncr.34459
- By:
- Publication type:
- Article
Towards better combination regimens of cytarabine and FLT3 inhibitors in acute myeloid leukemia.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2020, v. 86, n. 3, p. 325, doi. 10.1007/s00280-020-04114-z
- By:
- Publication type:
- Article
Effect of Incorporation of Pretreatment Serum Carcinoembryonic Antigen Levels Into AJCC Staging for Colon Cancer on 5-Year Survival.
- Published in:
- JAMA Surgery, 2015, v. 150, n. 8, p. 747, doi. 10.1001/jamasurg.2015.0871
- By:
- Publication type:
- Article
Between a rux and a hard place: evaluating salvage treatment and outcomes in myelofibrosis after ruxolitinib discontinuation.
- Published in:
- 2018
- By:
- Publication type:
- journal article